Mitsubishi Tanabe Unit Plans 40% Growth In Generics Portfolio In 10 Years
This article was originally published in PharmAsia News
Mitsubishi Tanabe Pharma Group's generics subsidiary plans a 40% increase in its portfolio within the next 10 years to take advantage of what is expected to be an expanded market for the drugs.
You may also be interested in...
A lengthening list of concession prices granted in the UK this year has added to the burden on pharmacists, according to the annual report of the country’s Pharmaceutical Services Negotiating Committee.
ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs. See what the CFO said about it here.
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.